How to Get Finasteride in Idaho

What Is Finasteride and Why Do Idaho Residents Need a Prescription?

Finasteride is a 5-alpha reductase type II inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT). The FDA first approved it at 5 mg (Proscar) for BPH in 1992, then at 1 mg (Propecia) for male-pattern hair loss in 1997 [1]. Because it alters androgen metabolism and carries a required Medication Guide disclosing sexual side effects and, at the 5 mg dose, a small signal for high-grade prostate cancer, federal law classifies it as a prescription-only medication in all 50 states, including Idaho [1].

Idaho follows federal Controlled Substances Act scheduling. Finasteride is not a controlled substance, so prescribers face no DEA quotas or triplicate-paper requirements. Any Idaho-licensed MD, DO, NP, or PA with prescriptive authority can write for it, and any Idaho-licensed pharmacy can dispense it [2].

The clinical rationale for prescribing is straightforward. In a 48-week randomized controlled trial by Kaufman et al. (N=1,553), men receiving finasteride 1 mg daily showed a mean increase of 107 hair counts per cm² vs. a loss of 23 hair counts in the placebo group (P<0.001) [3]. That magnitude of response, combined with a safety profile established across two decades of post-marketing data, makes finasteride the first-line pharmacologic option recommended by the American Academy of Dermatology for androgenetic alopecia in men [4].

Idaho Prescribing Laws: Who Can Write the Prescription?

Any of four license types may prescribe finasteride in Idaho: MD, DO, NP (nurse practitioner), or PA (physician assistant). Idaho Code § 54-1402 grants NPs full independent prescriptive authority once they hold an Advanced Practice Registered Nurse certificate and a DEA number where required [2]. PAs prescribe under a delegation agreement with a supervising physician per Idaho Code § 54-1806 [5].

Telehealth prescribing is explicitly permitted. Idaho adopted synchronous and asynchronous telehealth standards under Idaho Code § 54-5701 through § 54-5706, and the Idaho Board of Medicine has confirmed that a valid prescriber-patient relationship can be established via telehealth video or phone for non-controlled medications like finasteride [5]. You do not need a prior in-person visit. The prescriber must document a clinical evaluation, including a review of symptoms, relevant history, and any contraindications, before sending the prescription to your chosen pharmacy.

The table below summarizes the Idaho license types and their prescriptive scope for finasteride.

| License Type | Independent Rx Authority | Supervision Required | |---|---|---| | MD / DO | Yes | No | | NP (APRN) | Yes (post-certification) | No | | PA | Yes | Delegation agreement with MD/DO |

How to Get a Finasteride Prescription in Idaho: Step-by-Step

Getting finasteride in Idaho follows a short, predictable path regardless of whether you choose in-person or telehealth care.

Step 1. Choose your care channel. In-person visits are available through primary care physicians, urologists, and dermatologists across Idaho. Telehealth platforms licensed in Idaho can complete the entire evaluation via video or an asynchronous questionnaire reviewed by an Idaho-licensed provider.

Step 2. Complete the intake evaluation. The prescriber reviews your symptom history (hair loss pattern for AGA, urinary symptoms for BPH), current medications, and any personal or family history of prostate cancer. For BPH or any man over 40, a baseline PSA is standard before starting the 5 mg dose because finasteride approximately halves PSA values, which can mask early prostate cancer if a post-treatment baseline is not documented [6].

Step 3. Receive your prescription. Idaho law permits e-prescribing for non-controlled substances. The provider sends the script directly to your chosen pharmacy, or you can request a paper copy.

Step 4. Pick up or receive your medication. In-person pharmacies in Boise, Meridian, Nampa, Idaho Falls, Coeur d'Alene, and across the state stock generic finasteride. Mail-order pharmacies licensed in Idaho can ship to any address in the state within 1, 3 business days.

Step 5. Schedule a follow-up. Most protocols call for a follow-up at 3 months and again at 12 months to assess response and check PSA trend [6].

Labs Required Before Starting Finasteride in Idaho

Labs are not universally mandatory before the 1 mg dose, but they are strongly recommended before the 5 mg dose and for any man over 40 regardless of dose. The American Urological Association (AUA) 2023 guideline on BPH states that a serum PSA should be obtained before initiating 5-alpha reductase inhibitor therapy to establish a corrected baseline [6]. After 6 to 12 months of treatment, PSA values should be doubled to derive the "finasteride-adjusted PSA" for ongoing prostate cancer surveillance [6].

Standard pre-treatment labs for finasteride in Idaho include:

• Serum PSA (baseline, mandatory for BPH indication; recommended for AGA in men over 40)
• Basic metabolic panel or liver function tests (only if hepatic disease is suspected, since finasteride is hepatically metabolized via CYP3A4)
• Testosterone (optional; ordered when comorbid hypogonadism is suspected or when the patient is also a TRT candidate)

Most telehealth platforms in Idaho partner with national lab networks including LabCorp and Quest Diagnostics. Results typically return within 24 to 48 hours, and the provider reviews them before finalizing the prescription [7].

The FDA label specifies that finasteride is contraindicated in women who are or may become pregnant due to risk of external male genital birth defects in a male fetus [1]. For the rare case of a transgender female patient inquiring about finasteride in a feminizing hormone context, a separate evaluation including reproductive counseling is required before prescribing.

Telehealth Providers Prescribing Finasteride in Idaho

Several national telehealth platforms hold Idaho licenses and can prescribe finasteride without requiring an in-person visit. Under Idaho's telehealth statute, the provider must be licensed in Idaho, must document a clinical evaluation, and must offer a pathway for the patient to ask follow-up questions [5].

When comparing telehealth platforms, ask these specific questions:

1. Is the reviewing clinician licensed in Idaho specifically?
2. Does the platform send prescriptions to your local Idaho pharmacy, or do they require their own mail-order affiliate?
3. Is the visit fee separate from the medication cost?
4. What is the follow-up protocol if you develop side effects?

Asynchronous (questionnaire-based) platforms typically charge a flat monthly fee of $15, $35 for finasteride 1 mg, which may or may not include the cost of the tablet. Synchronous (live video) visits through platforms like HealthRX typically complete the initial evaluation in under 20 minutes and issue a same-day prescription [8].

Idaho Medicaid does not currently cover finasteride for male-pattern hair loss. Coverage for the 5 mg dose in BPH may be available under some Idaho Medicaid managed-care plans with prior authorization; beneficiaries should call the number on the back of their Medicaid card to verify formulary status before the prescriber submits the script [9].

Finasteride Pharmacies in Idaho: Retail, Mail-Order, and 503A Compounding

Any pharmacy holding an active Idaho Board of Pharmacy license may dispense FDA-approved generic finasteride. The generic 1 mg tablet is widely available and listed on the $4/$10 generic programs at major chains operating in Idaho, including Walmart Pharmacy, Costco Pharmacy, and Fred Meyer Pharmacy. Cash prices without insurance for a 30-day supply of generic finasteride 1 mg run approximately $10, $28 depending on the dispensing pharmacy and the coupon program used (GoodRx, RxSaver, etc.) [10].

503A compounding pharmacies in Idaho are licensed by the Idaho Board of Pharmacy and are distinct from 503B outsourcing facilities. A 503A pharmacy can compound finasteride in customized doses, delivery forms (for example, a topical solution for patients who wish to minimize systemic absorption), or combined formulations (for example, finasteride plus minoxidil in a single topical vehicle) when a valid prescription specifies a clinical need for the compounded form [11]. The FDA does not approve compounded drugs, so efficacy and safety data are extrapolated from the FDA-approved reference product [11].

Topical finasteride has attracted growing research interest. A 2021 randomized trial published in JAMA Dermatology (N=323) found that topical finasteride 0.25% spray applied once daily produced hair-count outcomes comparable to oral finasteride 1 mg daily while generating lower serum DHT suppression, suggesting reduced systemic exposure [12]. Idaho 503A pharmacies can prepare this formulation with a valid prescription specifying the clinical rationale (for example, documented intolerance to the oral form).

Mail-order pharmacies licensed to ship into Idaho must hold an out-of-state pharmacy permit from the Idaho Board of Pharmacy. They may ship finasteride to any Idaho residential address, typically within 3 business days via USPS or UPS. Controlled cold-chain storage is not required for finasteride tablets (store at 59, 86°F per USP guidelines) [1].

Transferring a Finasteride Prescription to Idaho

If you currently have a finasteride prescription from another state and are relocating to Idaho, you have several options. Under Idaho Pharmacy Rules (IDAPA 27.01.01), a pharmacist in Idaho may transfer a prescription from an out-of-state pharmacy for a non-controlled substance one time, provided the original prescription was issued by a prescriber licensed in their state of practice [2]. The receiving Idaho pharmacy contacts the originating pharmacy directly; you do not need to return to the original prescriber.

If the original prescription has no remaining refills, you need a new evaluation. A telehealth visit with an Idaho-licensed provider resolves this in one day, and the new prescription can be sent to your Idaho pharmacy the same day [5]. Keep a copy of your prior pharmacy records, including dose, duration of therapy, and any PSA values obtained during treatment. This speeds up the new prescriber's intake process and avoids duplicating labs you may have had within the past 6 months.

Dosing, Timelines, and What to Expect Clinically

The approved oral doses are 1 mg daily for AGA and 5 mg daily for BPH. Both are taken without regard to meals [1]. Finasteride does not require titration. You start at the full therapeutic dose on day one.

Timeline for AGA:

• Weeks 1, 12: No visible change. Shedding may temporarily increase as the hair cycle resets. This is normal and does not mean the drug is failing [4].
• Months 3, 6: Stabilization of further loss; early regrowth in some patients.
• Month 12: Full assessment of response. Kaufman et al. reported that 83% of men taking finasteride 1 mg maintained or increased hair count at 12 months vs. 28% in the placebo group [3].
• Ongoing: The drug requires continuous use. Hair lost before treatment and hair gained on treatment will shed within 12 months of stopping finasteride [4].

Timeline for BPH:

• Weeks 1, 4: No significant urinary symptom change expected.
• Months 3, 6: PSA falls by approximately 50%. Urinary flow rate and symptom scores begin to improve.
• Year 1, 2: The PLESS trial (N=3,040) showed that finasteride 5 mg reduced the risk of acute urinary retention and BPH-related surgery by approximately 55% and 34%, respectively, compared to placebo over 4 years [13].

The most commonly reported adverse effects in clinical trials are sexual in nature: decreased libido (reported by 1.8% on drug vs. 1.3% on placebo in the key 1-mg trial), erectile dysfunction (1.3% vs. 0.7%), and ejaculation disorder (1.2% vs. 0.7%) [1]. These rates are low, but patients should receive the FDA-mandated Medication Guide at dispensing and be encouraged to report any persistent sexual symptoms to their prescriber [1].

Post-finasteride syndrome is a patient-reported condition characterized by persistent sexual, neurological, and psychiatric symptoms after stopping finasteride. The FDA updated the drug label in 2011 to note reports of persistent sexual dysfunction after discontinuation [1]. The NIDDK-funded research on this topic is ongoing, and prescribers in Idaho should document a baseline sexual function assessment before initiating therapy so that any change can be attributed accurately [14].

Prior Authorization for Finasteride in Idaho

Idaho commercial insurance plans rarely require prior authorization (PA) for generic finasteride 5 mg when prescribed for BPH, as it sits on most Tier 1 generic formularies. For the 1 mg dose prescribed for AGA, many commercial plans classify it as a cosmetic indication and exclude it from coverage entirely [9].

When prior authorization is required, the standard documentation package includes:

1. The ICD-10 diagnosis code (L64.0 for drug-induced androgenetic alopecia; L64.9 for androgenetic alopecia, unspecified; N40.1 for BPH with lower urinary tract symptoms).
2. A letter of medical necessity from the prescriber.
3. Documentation of trial and failure of first-line therapy if applicable (for BPH: alpha-blockers such as tamsulosin).
4. Baseline PSA value (required by most plans for 5 mg).

Idaho Medicaid (Medicaid Managed Care through Centene/Magnolia Health or Molina Healthcare of Idaho) does not list finasteride for AGA on the preferred drug list as of the most recent published formulary [9]. Patients paying cash for generic 1 mg finasteride at Idaho pharmacies typically spend less on a 90-day supply than the cost and time required to pursue a PA, making cash-pay the pragmatic choice for AGA.

Safety Monitoring and Long-Term Use in Idaho

Long-term use of finasteride is well-supported by clinical evidence. The 5-year data from the Prostate Cancer Prevention Trial (PCPT, N=18,882) showed that finasteride reduced prostate cancer detection by 24.8% overall but produced a small increase in high-grade (Gleason 7, 10) cancers in the treated group, an effect now attributed partly to detection bias from the lower PSA and smaller prostate volume in the finasteride arm [15]. The FDA reviewed this data and concluded that finasteride should not be used to prevent prostate cancer; the prescriber should disclose this to any patient on long-term 5 mg therapy [1].

Annual PSA monitoring is recommended for men on finasteride 5 mg. The corrected PSA (multiply observed value by 2.0 after 6 to 12 months of therapy) should be trended the same way as an untreated man's PSA [6]. Any rise in the corrected PSA despite continued therapy warrants urology referral.

For finasteride 1 mg used for AGA, the prostate cancer signal is not a concern at the approved dose; the 5-year Prostate Cancer Prevention Trial used 5 mg, which produces substantially greater DHT suppression than 1 mg [15]. Annual dermatology or primary care follow-up to assess response and reassess the benefit-risk balance is sufficient [4].